Literature DB >> 8749157

Thresholds for perception of lateral motion in normal subjects and patients with bilateral loss of vestibular function.

C C Gianna1, S Heimbrand, T Nakamura, M A Gresty.   

Abstract

Thresholds for detection of direction of whole-body lateral linear acceleration were determined for normal (N) and labyrinthine defective (LD) subjects. Thresholds for 67% correct detection of direction of acceleration steps for 5 LDs (mean 5.65 cm/s2, peak gradient = 25 cm/s3) were not significantly different from 8 Ns (mean 4.84 cm/s2, peak gradient = 22 cm/s3). High inter-subject variability was found both among the 7 Ns and 3 LDs for detection of parabolic accelerations with some individuals being unable to detect their motion direction. Mean Ns thresholds were 15.2 cm/s2 for a ramp with gradient of acceleration = 2.8 cm/s3, 26.4 cm/s2 for a ramp with gradient = 7.9 cm/s3 and 20.2 cm/s2 for a parabola with second derivative = 1.52 cm/s4. Thresholds for LDs were respectively 19.1 cm/s2, 32 cm/s2 and 26.7 cm/s2. The lower thresholds for acceleration steps demonstrate the important effect of acceleration gradient on motion detection. For all stimuli, thresholds for some LDs could be in the range of Ns showing that somatosensory signals can play a significant role in detecting lateral acceleration.

Entities:  

Mesh:

Year:  1995        PMID: 8749157     DOI: 10.3109/00016489509125266

Source DB:  PubMed          Journal:  Acta Otolaryngol Suppl        ISSN: 0365-5237


  3 in total

1.  Limited interaction between translation and visual motion aftereffects in humans.

Authors:  Benjamin T Crane
Journal:  Exp Brain Res       Date:  2012-10-14       Impact factor: 1.972

2.  Fore-aft translation aftereffects.

Authors:  Benjamin T Crane
Journal:  Exp Brain Res       Date:  2012-05-05       Impact factor: 1.972

3.  Thresholds for perception of direction of linear acceleration as a possible evaluation of the otolith function.

Authors:  H Kingma
Journal:  BMC Ear Nose Throat Disord       Date:  2005-06-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.